FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236382079> ?p ?o ?g. }

• W4236382079 abstract "Background Memory disorder is one of the most frequent cognitive impairment and has a great negative impact on the quality of life in patients with multiple sclerosis (MS). A few pharmacologic agents appear to be effective to memory disorder in patients with MS in some existing randomised controlled trials. Objectives To assess the absolute and comparative efficacy, tolerability and safety of pharmacologic treatments for memory disorder in adult patients with MS. Search methods We searched the Cochrane Multiple Sclerosis Group's Trials Register (17 January 2011), PsycINFO (January 1980 ‐ April Week 4 2011) and CBMdisc (January 1978 ‐ 6 April 2011), and checked reference lists of identified articles, searched some relevant journals manually, registers of clinical trials and published abstracts of conference proceedings. Selection criteria All double‐blind, randomized controlled parallel trials on pharmacologic treatment versus placebo treatment or no treatment or one or more pharmacologic treatments, without restrictions regarding dose, route of administration and frequency, administration duration≥12 weeks for memory disorder in adult patients with MS who display at least mild memory impairment at 0.5 standard deviations below age ‐and‐sex‐based normative data on a validated memory scale. Adequately randomized or quasi‐randomized trials were included. Data collection and analysis Two review authors independently assessed trial quality and extracted data. Disagreements were discussed and resolved by consensus among review authors. Principal investigators of included studies were contacted for additional data or confirmation. Main results Four RCTs involving adult patients with all the types of MS and at least mild memory impairment were included, evaluating donepezil, Ginkgo biloba (GB), memantine and rivastigmine respectively vs placebo in treating memory disorder in MS.There were no serious adverse events in intervention groups.The quality of the included studies was overall low, some of important variables were not matched between groups at baseline, the samples of subjects were relatively small and the follow‐up was short. Three RCTs which evaluate GB, memantine, rivastigmine respectively vs placebo are currently ongoing. Authors' conclusions Until the results of ongoing studies are available, there is no convincing evidence to support pharmacologic intervention as an effective treatment for memory disorder in MS patients. However, donepezil, Ginkgo biloba, memantine and rivastigmine resulted to be safe and well tolerated as adverse events such as nausea, diarrhea, somnolence, and constipation were not frequent, while no serious adverse effects were reported. Future high quality randomised controlled trials are needed." @default.
• W4236382079 created "2022-05-12" @default.
• W4236382079 creator A5002478194 @default.
• W4236382079 creator A5004691448 @default.
• W4236382079 creator A5030769859 @default.
• W4236382079 creator A5047219100 @default.
• W4236382079 creator A5077145485 @default.
• W4236382079 date "2011-10-05" @default.
• W4236382079 modified "2023-10-17" @default.
• W4236382079 title "Pharmacologic treatment for memory disorder in multiple sclerosis" @default.
• W4236382079 cites W1500818454 @default.
• W4236382079 cites W1847712199 @default.
• W4236382079 cites W1934404972 @default.
• W4236382079 cites W1964879289 @default.
• W4236382079 cites W1973239226 @default.
• W4236382079 cites W1973352717 @default.
• W4236382079 cites W1978392406 @default.
• W4236382079 cites W1982245677 @default.
• W4236382079 cites W1983187546 @default.
• W4236382079 cites W1985050648 @default.
• W4236382079 cites W1996011091 @default.
• W4236382079 cites W1997697006 @default.
• W4236382079 cites W1997813030 @default.
• W4236382079 cites W2003189347 @default.
• W4236382079 cites W2004854966 @default.
• W4236382079 cites W2007948644 @default.
• W4236382079 cites W2016109278 @default.
• W4236382079 cites W2016697624 @default.
• W4236382079 cites W2019602007 @default.
• W4236382079 cites W2030907857 @default.
• W4236382079 cites W2036272035 @default.
• W4236382079 cites W2036284753 @default.
• W4236382079 cites W2037196923 @default.
• W4236382079 cites W2039736060 @default.
• W4236382079 cites W2043322849 @default.
• W4236382079 cites W2051635625 @default.
• W4236382079 cites W2052638649 @default.
• W4236382079 cites W2056736742 @default.
• W4236382079 cites W2057005657 @default.
• W4236382079 cites W2062453566 @default.
• W4236382079 cites W2065806194 @default.
• W4236382079 cites W2066056333 @default.
• W4236382079 cites W2066108884 @default.
• W4236382079 cites W2066115280 @default.
• W4236382079 cites W2073413249 @default.
• W4236382079 cites W2074567403 @default.
• W4236382079 cites W2081741293 @default.
• W4236382079 cites W2105490558 @default.
• W4236382079 cites W2108442841 @default.
• W4236382079 cites W2110421515 @default.
• W4236382079 cites W2110690684 @default.
• W4236382079 cites W2117268408 @default.
• W4236382079 cites W2119882806 @default.
• W4236382079 cites W2122410353 @default.
• W4236382079 cites W2127086238 @default.
• W4236382079 cites W2130355701 @default.
• W4236382079 cites W2151846232 @default.
• W4236382079 cites W2152215092 @default.
• W4236382079 cites W2162739815 @default.
• W4236382079 cites W2916040650 @default.
• W4236382079 doi "https://doi.org/10.1002/14651858.cd008876.pub2" @default.
• W4236382079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21975787" @default.
• W4236382079 hasPublicationYear "2011" @default.
• W4236382079 type Work @default.
• W4236382079 citedByCount "5" @default.
• W4236382079 countsByYear W42363820792015 @default.
• W4236382079 countsByYear W42363820792016 @default.
• W4236382079 countsByYear W42363820792020 @default.
• W4236382079 countsByYear W42363820792021 @default.
• W4236382079 crossrefType "reference-entry" @default.
• W4236382079 hasAuthorship W4236382079A5002478194 @default.
• W4236382079 hasAuthorship W4236382079A5004691448 @default.
• W4236382079 hasAuthorship W4236382079A5030769859 @default.
• W4236382079 hasAuthorship W4236382079A5047219100 @default.
• W4236382079 hasAuthorship W4236382079A5077145485 @default.
• W4236382079 hasConcept C118552586 @default.
• W4236382079 hasConcept C126322002 @default.
• W4236382079 hasConcept C142724271 @default.
• W4236382079 hasConcept C168563851 @default.
• W4236382079 hasConcept C169900460 @default.
• W4236382079 hasConcept C1862650 @default.
• W4236382079 hasConcept C187212893 @default.
• W4236382079 hasConcept C197934379 @default.
• W4236382079 hasConcept C204787440 @default.
• W4236382079 hasConcept C27081682 @default.
• W4236382079 hasConcept C2778375690 @default.
• W4236382079 hasConcept C3018842126 @default.
• W4236382079 hasConcept C535046627 @default.
• W4236382079 hasConcept C71924100 @default.
• W4236382079 hasConcept C95190672 @default.
• W4236382079 hasConceptScore W4236382079C118552586 @default.
• W4236382079 hasConceptScore W4236382079C126322002 @default.
• W4236382079 hasConceptScore W4236382079C142724271 @default.
• W4236382079 hasConceptScore W4236382079C168563851 @default.
• W4236382079 hasConceptScore W4236382079C169900460 @default.
• W4236382079 hasConceptScore W4236382079C1862650 @default.
• W4236382079 hasConceptScore W4236382079C187212893 @default.
• W4236382079 hasConceptScore W4236382079C197934379 @default.
• W4236382079 hasConceptScore W4236382079C204787440 @default.
• W4236382079 hasConceptScore W4236382079C27081682 @default.

• next